R-CHOP
E261830
R-CHOP is a standard chemotherapy regimen combining rituximab with multiple cytotoxic drugs, commonly used to treat non-Hodgkin lymphoma.
All labels observed (3)
| Label | Occurrences |
|---|---|
| CHOP chemotherapy regimen | 1 |
| R-CHOP canonical | 1 |
| R-CHOP chemotherapy regimen | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T2371047 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: R-CHOP Context triple: [Rituxan, combinationRegimen, R-CHOP]
-
A.
Alimta
Alimta is a chemotherapy drug (pemetrexed) primarily used to treat malignant pleural mesothelioma and non-small cell lung cancer.
-
B.
Rituxan
Rituxan is a monoclonal antibody drug (rituximab) widely used to treat certain blood cancers and autoimmune diseases by targeting the CD20 protein on B cells.
-
C.
Xeloda
Xeloda is an oral chemotherapy drug (capecitabine) commonly used to treat various cancers, including colorectal and breast cancer.
-
D.
Imbruvica
Imbruvica is a targeted cancer therapy (a Bruton's tyrosine kinase inhibitor) used primarily to treat certain types of blood cancers such as mantle cell lymphoma and chronic lymphocytic leukemia.
-
E.
bortezomib
Bortezomib is a proteasome inhibitor chemotherapy drug primarily used in the treatment of multiple myeloma and certain types of lymphoma.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: R-CHOP Target entity description: R-CHOP is a standard chemotherapy regimen combining rituximab with multiple cytotoxic drugs, commonly used to treat non-Hodgkin lymphoma.
-
A.
Alimta
Alimta is a chemotherapy drug (pemetrexed) primarily used to treat malignant pleural mesothelioma and non-small cell lung cancer.
-
B.
Rituxan
Rituxan is a monoclonal antibody drug (rituximab) widely used to treat certain blood cancers and autoimmune diseases by targeting the CD20 protein on B cells.
-
C.
Xeloda
Xeloda is an oral chemotherapy drug (capecitabine) commonly used to treat various cancers, including colorectal and breast cancer.
-
D.
Imbruvica
Imbruvica is a targeted cancer therapy (a Bruton's tyrosine kinase inhibitor) used primarily to treat certain types of blood cancers such as mantle cell lymphoma and chronic lymphocytic leukemia.
-
E.
bortezomib
Bortezomib is a proteasome inhibitor chemotherapy drug primarily used in the treatment of multiple myeloma and certain types of lymphoma.
- F. None of above. chosen
Statements (48)
| Predicate | Object |
|---|---|
| instanceOf |
cancer treatment protocol
ⓘ
chemotherapy regimen ⓘ |
| alternativeSchedule | 14-day cycle (R-CHOP-14) ⓘ |
| commonAdverseEffect |
alopecia
ⓘ
cardiotoxicity from doxorubicin ⓘ immunosuppression and infection risk ⓘ myelosuppression ⓘ nausea and vomiting ⓘ peripheral neuropathy ⓘ |
| containsAlkylatingAgent | cyclophosphamide ⓘ |
| containsAnthracycline | doxorubicin ⓘ |
| containsCorticosteroid | prednisone ⓘ |
| containsMonoclonalAntibody |
rituximab
ⓘ
linked to:
Rituxan
|
| containsVincaAlkaloid | vincristine ⓘ |
| fullName | rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone ⓘ |
| hasAbbreviationLetterMeaning |
C stands for cyclophosphamide
ⓘ
H stands for hydroxydaunorubicin (doxorubicin) ⓘ O stands for Oncovin (vincristine) ⓘ P stands for prednisone ⓘ R stands for rituximab ⓘ |
| hasComponentRole |
cyclophosphamide is an alkylating cytotoxic agent
ⓘ
doxorubicin is a DNA-intercalating anthracycline ⓘ prednisone is an immunosuppressive corticosteroid ⓘ rituximab is an anti-CD20 monoclonal antibody ⓘ vincristine is a microtubule inhibitor ⓘ |
| includesDrug |
cyclophosphamide
ⓘ
doxorubicin ⓘ prednisone ⓘ rituximab ⓘ
linked to:
Rituxan
vincristine ⓘ |
| oftenCombinedWith | growth factor support in dose-dense regimens ⓘ |
| requiresMonitoringOf |
cardiac function
ⓘ
complete blood count ⓘ liver function tests ⓘ |
| routeOfAdministration |
intravenous
ⓘ
oral ⓘ |
| standardOfCareFor | first-line treatment of diffuse large B-cell lymphoma ⓘ |
| targetsMolecule | CD20 antigen on B cells ⓘ |
| treatmentIntent | curative in many aggressive B-cell lymphomas ⓘ |
| treatmentSetting | systemic therapy ⓘ |
| typicalCycleLength | 21 days ⓘ |
| typicalNumberOfCycles |
6 cycles
ⓘ
8 cycles ⓘ |
| usedForTreatmentOf |
CD20-positive B-cell lymphomas
ⓘ
diffuse large B-cell lymphoma ⓘ
linked to:
non-Hodgkin lymphoma
follicular lymphoma ⓘ mantle cell lymphoma ⓘ non-Hodgkin lymphoma ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: R-CHOP Description of subject: R-CHOP is a standard chemotherapy regimen combining rituximab with multiple cytotoxic drugs, commonly used to treat non-Hodgkin lymphoma.
Referenced by (3)
Full triples — surface form annotated when it differs from this entity's canonical label.
linked to: R-CHOP
linked to: R-CHOP